Frontiers Winter 2018
Changing of the Guard
With the changing of the year comes a changing of the guard at The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James).
While we are saddened by the impending departure of former OSUCCC Director and James CEO Michael A. Caligiuri, MD, who in February will embark on a new career opportunity in California, we are also honored to have been chosen to guide Ohio State’s cancer program in pursuit of our shared vision of a cancer-free world.
The OSUCCC – James flourished under Dr. Caligiuri’s leadership, enjoying record financial performance, earning the highest possible descriptor of “exceptional” during our two most recent NCI surveys, receiving patient-satisfaction scores that rank among the nation’s highest, and gaining a reputation as one of the most translational cancer hospitals in the country as we readily convert laboratory discoveries into innovative cancer care and prevention strategies.
Through the combined efforts of our dedicated faculty, staff and volunteers, we intend to build upon the outstanding reputation of the OSUCCC – James as a transformational cancer hospital that provides compassionate cancer care to the patients and families who turn to us for help.
We offer evidence of our commitment in this issue of Frontiers. Here you can gain insight into the RAS oncogene—which when mutated drives some of the deadliest forms of cancer—and our researchers’ efforts to discover an effective inhibitor to blunt its oncogenic effects. You can also read about our recently launched Digital Pathology Program that will fully digitize our anatomical pathology services over the next 10 years.
Excitement is mounting at the OSUCCC – James, and we thank you for sharing in it by taking time to peruse this edition of Frontiers.